Loading...
XKRX
068760
Market cap1.30bUSD
Apr 11, Last price  
46,900.00KRW
1D
-0.85%
1Q
-17.57%
Jan 2017
96.23%
IPO
376.29%
Name

Celltrion Pharm Inc

Chart & Performance

D1W1MN
P/E
86.99
P/S
4.76
EPS
539.14
Div Yield, %
—
Shrs. gr., 5y
-0.95%
Rev. gr., 5y
21.49%
Revenues
477.84b
+22.90%
46,967,59652,657,24866,744,35374,732,429,050104,811,184,059135,860,255,627146,880,153,915173,512,796,760233,568,477,708398,738,209,298386,039,612,595388,794,335,490477,835,307,770
Net income
21.97b
+3.30%
3,551,9382,613,0595,869,4456,733,913,573-21,105,977,9502,714,764,747-9,388,770,7458,602,167,88220,939,675,88034,578,715,48025,959,948,29021,264,988,85021,966,117,520
CFO
56.59b
+3,018.35%
-5,881,811-65,892,77517,325,7748,375,907,015-26,209,044,191-10,163,098,9108,598,614,65521,948,673,77930,610,609,80387,775,503,787-9,227,248,1631,814,680,96556,588,067,880
Dividend
Dec 27, 200698.7504 KRW/sh
Earnings
May 14, 2025

Profile

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea.
URL
https://www.celltrionph.com/ko-kr/home/index
IPO date
Feb 03, 2006
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
477,835,308
22.90%
388,794,335
0.71%
386,039,613
-3.18%
Cost of revenue
400,740,168
316,967,316
316,909,605
Unusual Expense (Income)
NOPBT
77,095,140
71,827,019
69,130,007
NOPBT Margin
16.13%
18.47%
17.91%
Operating Taxes
7,793,175
4,943,881
4,508,726
Tax Rate
10.11%
6.88%
6.52%
NOPAT
69,301,965
66,883,138
64,621,282
Net income
21,966,118
3.30%
21,264,989
-18.09%
25,959,948
-24.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
(4,047,083)
(3,716,888)
(3,722,617)
BB yield
0.16%
0.10%
0.14%
Debt
Debt current
157,081,745
156,664,955
138,874,376
Long-term debt
32,376,548
10,239,311
21,822,998
Deferred revenue
8,307,761
8,716,885
8,231,481
Other long-term liabilities
1,493,600
1,053,694
885,068
Net debt
143,748,130
128,266,704
110,054,871
Cash flow
Cash from operating activities
56,588,068
1,814,681
(9,227,248)
CAPEX
(4,942,148)
(6,898,264)
(6,285,624)
Cash from investing activities
(12,116,189)
(5,536,176)
(15,410,377)
Cash from financing activities
(18,706,104)
(7,957,966)
(24,155,341)
FCF
67,686,249
26,493,985
13,278,638
Balance
Cash
69,599,670
37,133,512
49,068,034
Long term investments
(23,889,507)
1,504,049
1,574,468
Excess cash
21,818,398
19,197,845
31,340,522
Stockholders' equity
153,306,665
131,249,799
115,506,899
Invested Capital
557,075,712
530,332,149
489,467,273
ROIC
12.75%
13.12%
13.80%
ROCE
13.32%
13.07%
13.27%
EV
Common stock shares outstanding
43,464
39,453
41,515
Price
56,700.00
-38.50%
92,200.00
44.71%
63,714.29
-48.78%
Market cap
2,464,411,011
-32.25%
3,637,536,082
37.52%
2,645,077,278
-48.94%
EV
2,608,159,141
3,765,802,786
2,755,132,149
EBITDA
97,187,980
91,552,042
86,548,572
EV/EBITDA
26.84
41.13
31.83
Interest
7,505,504
8,290,134
6,216,884
Interest/NOPBT
9.74%
11.54%
8.99%